# CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC

> **NCT06557096** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital of Nanchang University** · enrollment: 100 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer
- Circulating Tumor Cell
- EGF-R Positive Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Osimertinib 80 MG
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT06557096
- **Lead sponsor:** Second Affiliated Hospital of Nanchang University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-08-20
- **Primary completion:** 2027-06-01
- **Final completion:** 2028-07-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-08-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06557096

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06557096, "CSF CTC-Capture-Guided EGFR-TKI and Bevacizumab Combination Therapy in EGFR-Mutant Advanced NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06557096. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*